Aug. 14 at 8:55 PM
$ELTP Consolidated revenues for the three-month period ending June 30, 2025, were
$40.2 million, an increase of
$21.4 million or approximately 114% as compared to the comparable period of the prior fiscal year. Operating profits were
$21.7 million, an increase of
$17.8 million or approximately 462%, as compared to the comparable period of the prior fiscal year. The increase in operating profits was primarily attributed to sales of Elite's lisdexamfetamine products, which were launched after the comparable period of the prior fiscal year, as well as overall strong growth in the Elite label product lines as compared to the comparable period in the prior fiscal yea ...